Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial

July 13, 2026 10:30 AM EDT News Briefing Tris Phar­ma's CRL for nar­colep­sy drug; Agenus aban­dons Phase 3 CRC tri­al ENDPOINTS Plus, news about In­sil­i­co, Ipsen, Q32 Bio, GSK’s Jem­per­li, Drug Farm and Pad­cev. ❌ FDA re­jects Tris Phar­ma’s nar­colep­sy drug: Its Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER